Servier, a Paris-based international pharmaceutical company governed by the non-profit FIRS (Fondation Internationale de Recherche Servier), has the mission to drive therapeutic progress which will serve patient needs. Operating in nearly 70 countries with drugs available in 140, Servier achieved over €5.9 billion in turnover and €1.320 billion in EBITDA in fiscal 2024. Ten countries generated over €100 million in turnover each. At end of May YTD results show an uplift compared to both FY23/24 and budget. In just eight months, the Group has already reached last year’s full-year EBITDA level, with a different TA split. 

Employing over 22,000 globally (5,000 in France), the independent company reinvests 20% of its non-generics turnover in R&D. This investment fuels innovation and ensures future sustainability. In addition, the Group’s generics portfolio, representing about a quarter of turnover, plays a key role in providing affordable treatments to millions of patients g...